Is Topical Calcipotriol A Better Option in Mild To Moderate Plaque Psoriasis? An Open Label, Randomized, Comparative Study

Authors: Sana Imran, Shamama Islam, Farhana Sami

1 Jinnah Sindh Medical University (JSMU), Karachi.
2 Jinnah Sindh Medical University (JSMU), Karachi.
3 Jinnah Sindh Medical University (JSMU), Karachi

Volume 23 | Issue 4

Published: October 27, 2026

Abstract

To evaluate whether topical Calcipotriol (0.005%) is a better option in the treatment of mild to moderate plaque psoriasis in an open label, randomized, comparative study. Study population: All outpatients visiting Department of Dermatology, JPMC, Karachi from April 2013 to September 2013. Materials and Methods: This open labeled, comparative 12 weeks research work was done in Basic Medical Science Institute (BMSI), Postgraduate Medical Centre (JPMC), Karachi in the Department of Pharmacology and Therapeutics. In the study, mild to moderate 80 enrolled plaque psoriasis patients were divided into topical Betamethasone valerate (0.1%) ointment treated group A patients and topical Calcipotriol (0.005%) ointment treated group B patients i.e 40 patients in each group. Psoriasis Area and Severity Index (PASI) parameter and adverse effects were analyzed in the study period. Results: Psoriasis Area and Severity Index (PASI) in group B patients, topical Calcipotriol ointment showed marked progress of 71.61% and 69.21% in Psoriasis Area and Severity Index (PASI) score in mild to moderate plaque psoriasis respectively as compared to group A patients, topical Betamethasone valerate ointment showed progress of 63.2% and 60.44% in Psoriasis Area and Severity Index (PASI) score in mild to moderate plaque psoriasis respectively. Conclusion: Topical Calcipotriol ointment was a better option regarding progress in Psoriasis Area and Severity Index (PASI) score and minimum adverse effects in mild to moderate plaque psoriatic patients.

Keywords: Calcipotriol ointment, Betamethasone valerate ointment, Plaque psoriasis, Psoriasis Area Severity Index (PASI) parameter, skin irritation, rashes, burning sensation, striae, telangiectasia.

DOI: (All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.)

Download Full Text PDF